Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30103276 | 0.89 | PDE7A (0.43) | ABCG2CSNK2A1KMT2ALMNA | |
| SCHEMBL23931443 | 0.89 | PDE7A (0.43) | ABCG2CSNK2A1KMT2ALMNA | |
| SCHEMBL30103185 | 0.89 | ABCG2 (0.42) | ABCG2CSNK2A1RAD52KMT2APIK3CD | |
| SCHEMBL24110797 | 0.89 | ABCG2 (0.42) | ABCG2CSNK2A1RAD52KMT2APIK3CD | |
| SCHEMBL30103301 | 0.88 | LMNA (0.38) | KMT2ALMNAPIK3CD | |
| SCHEMBL24111058 | 0.88 | LMNA (0.38) | KMT2ALMNAPIK3CD | |
| SCHEMBL30103212 | 0.87 | TDO2 (0.48) | RAD52KMT2A | |
| SCHEMBL23958205 | 0.87 | TDO2 (0.48) | RAD52KMT2A | |
| SCHEMBL24111041 | 0.86 | GPR6 (0.42) | GPR6ABCG2CSNK2A1PIK3CD | |
| SCHEMBL30103201 | 0.86 | GPR6 (0.42) | GPR6ABCG2CSNK2A1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
| WO-2021215537-A1 | 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | CRKL, CLIC4, CLIC1 | GPR6 1049/4885ABCG2 191/4885CSNK2A1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.